#BestACR20Tweets RT @SattuiSEMD :L06: Mavrilimumab in #GCA Efficacy+safety of MAV maintaining sustained remission 26w new and relapsing/ref #GCA Flare risk ➡️ 62% risk ⬇️ of flare w/ MAV Sustained remission➡️ 33% ⬆️ in MAV No diff in new/relapsing/ref pts, No diff in AE